1. Participants who are pregnant or are currently breastfeeding

2. History of sensitivity to study compound or any of their excipients

3. Previous intolerance to SCFA or related compounds

4. Current (within 3 months of screening) treatment with csDMARDs

5. Current or past (ever) treatment with biologic therapies (including but not limited to anti-TNF, anti-IL-17, anti-IL-12/23)

6. Current antibiotic treatment (within 3 months of screening)

7. Current consumption of probiotics (within 3 months of screening)

8. Severe hepatic impairment (eg, ascites and/or clinical signs of coagulopathy)

9. Renal failure (eGFR \<30 or requiring dialysis) by history

10. History of other autoimmune disease

11. Current immunodeficiency state (e.g., cancer, HIV, others)

A Pilot Proof of Concept Study of the Effects of Administration of SCFA in Rheumatoid Arthritis (EASi-RA)